550,000 Shares in Envista Holdings Corporation $NVST Purchased by Integral Health Asset Management LLC

Integral Health Asset Management LLC acquired a new stake in shares of Envista Holdings Corporation (NYSE:NVST) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 550,000 shares of the company’s stock, valued at approximately $11,204,000. Integral Health Asset Management LLC owned about 0.33% of Envista at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Norges Bank purchased a new stake in Envista during the second quarter valued at $40,229,000. ARGA Investment Management LP bought a new stake in Envista during the third quarter worth approximately $950,000. Massachusetts Financial Services Co. MA raised its position in Envista by 22.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,905,149 shares of the company’s stock valued at $59,178,000 after purchasing an additional 523,949 shares during the period. Jupiter Asset Management Ltd. raised its holdings in Envista by 24.6% during the 3rd quarter. Jupiter Asset Management Ltd. now owns 1,349,042 shares of the company’s stock valued at $27,480,000 after buying an additional 266,671 shares during the period. Finally, First Eagle Investment Management LLC purchased a new position in Envista during the third quarter worth $4,329,000.

Envista Stock Performance

Shares of NVST stock opened at $24.62 on Friday. The firm has a market cap of $4.03 billion, a price-to-earnings ratio of 87.91, a PEG ratio of 1.74 and a beta of 0.95. The company has a quick ratio of 2.04, a current ratio of 2.38 and a debt-to-equity ratio of 0.47. Envista Holdings Corporation has a 52-week low of $14.22 and a 52-week high of $30.42. The company’s 50 day moving average is $26.20 and its 200 day moving average is $22.58.

Envista (NYSE:NVST) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.During the same quarter in the previous year, the company posted $0.24 earnings per share. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, sell-side analysts anticipate that Envista Holdings Corporation will post 1 EPS for the current fiscal year.

Insider Activity at Envista

In related news, SVP Mischa Reis sold 9,675 shares of the stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $30.00, for a total transaction of $290,250.00. Following the completion of the sale, the senior vice president owned 32,382 shares of the company’s stock, valued at $971,460. This represents a 23.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.66% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on NVST. UBS Group increased their price objective on shares of Envista from $22.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 3rd. Wall Street Zen raised Envista from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 26th. Leerink Partners set a $35.00 price objective on Envista and gave the company an “outperform” rating in a research report on Friday, February 6th. Morgan Stanley set a $19.00 price target on shares of Envista in a research note on Friday, February 6th. Finally, Robert W. Baird set a $30.00 price objective on shares of Envista in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Envista currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.75.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.